Search results for: cmt
CMTA-STAR Alliance Partner NMD Pharma Shares New SYNAPSE-CMT Trial Data
NMD Pharma shared new data from its Phase 2a SYNAPSE-CMT clinical trial evaluating the investigational drug ignaseclant during a late-breaking presentation at the 2026 MDA Clinical & Scientific Conference.
CMTA-STAR Preclinical Toolbox: A Validated Human iPSC Motor Neuron Assay for CMT2A Now Available
CMTA has developed and validated a human iPSC-derived motor neuron assay for CMT2A in collaboration with ANANDA Devices and BrainXell. Now available through the CMTA-STAR Preclinical Toolbox, the platform enables parallel drug screening and direct visualization of mitochondrial mobility impairment in CMT2A patient-derived neurons.
CMTA Center of Excellence at Prosserman Centre for Neuromuscular Diseases
Appointments: Please send an Ocean eReferral or fax the completed referral form to Toronto General...
CMTA Board of Directors Welcomes New Chair and Two New Members
The Charcot-Marie-Tooth Association named Wendy Arnone as chair of its Board of Directors and appointed...
We Go Where the Science Goes: 2025 CMTA Research Highlights
By Katherine Forsey, PhD Each year, I’m reminded that progress in CMT research is built...
What Your Inner Ear Could Tell Us About CMT Treatment
Progress in treating CMT depends on finding therapies that work and measuring how well they...
The Last Mile: Delivering CMT Therapies to the Nerves in Need
Developing a treatment is only half the challenge. The other half is getting it to...
CMTA Invests $141,000 to Study Hearing and Balance to Develop Better Clinical Trial Outcome Measures in Charcot-Marie-Tooth Disease
CMTA is supporting a two-year research project examining hearing and balance signaling to strengthen outcome measures in future CMT clinical trials.
Hearing and Balance Biomarkers for Outcome Measure Development in CMT1A
With CMTA support of $141,000, researchers led by Gabriel Corfas, PhD, at the Kresge Hearing...
CMTA Appoints David Stark, MD, and Catherine Illingworth to Board of Directors, Expanding Clinical and Biotech Expertise
CMTA welcomes David Stark, MD, and Catherine Illingworth to its Board of Directors, strengthening clinical insight and gene therapy leadership within the CMT community.
